Monopar Therapeutics (MNPR) PT Raised to $100 at Chardan Capital Markets
Tweet Send to a Friend
Chardan Capital Markets analyst Keay Nakae raised the price target on Monopar Therapeutics (NASDAQ: MNPR) to $100.00 (from $85.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
